Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

SRP0363

Sigma-Aldrich

Cot active mouse

recombinant, expressed in baculovirus infected Sf9 cells, ≥50% (SDS-PAGE)

Synonym(s):

Cot, Map3k8, Tpl2, mitogen-activated protein kinase kinase kinase 8

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352202
NACRES:
NA.32

biological source

mouse

recombinant

expressed in baculovirus infected Sf9 cells

assay

≥50% (SDS-PAGE)

form

aqueous solution

mol wt

70 kDa

packaging

pkg of 10 μg

NCBI accession no.

NM_007746

UniProt accession no.

Q07174

shipped in

dry ice

storage temp.

−70°C

Gene Information

mouse ... MAP3K8(26410)

General description

Mouse Cot kinase (MAP3K8) (GenBank Accession No. NM_007746), amino acids 30-397 with N-terminal His-GST-tag, expressed in a Baculovirus infected Sf9 cell expression system.

Physical form

Formulated in 40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.4 mM KCl, 5 mM glutathione, 134 mM imidazole, 3 mM DTT and 20% glycerol.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360D

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
4105010901

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Irene Soria-Castro et al.
The Journal of biological chemistry, 285(44), 33805-33815 (2010-08-26)
Cot/tpl2 (also known as MAP3K8) has emerged as a new and potentially interesting therapeutic anti-inflammatory target. Here, we report the first study of Cot/tpl2 involvement in acute peripheral inflammation in vivo. Six hours after an intraplantar injection of zymosan, Cot/tpl2(-/-)
Joseph H Jeong et al.
PloS one, 6(1), e16205-e16205 (2011-01-27)
Despite its initial positive response to hormone ablation therapy, prostate cancers invariably recur in more aggressive, treatment resistant forms. The lack of our understanding of underlying genetic alterations for the transition from androgen-dependent (AD) to ADI prostate cancer growth hampers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service